Clinical trial readout dates for IDEAYA Biosciences Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.
| Phase 2/3 IDE196 Metastatic Uveal Melanoma · NCT05987332 | January 2027 Ongoing |
| Phase 1/2 IDE196 Metastatic Uveal Melanoma; Cutaneous Melanoma · NCT03947385 | January 2027 Recruiting |
| Phase 2 Darovasertib Uveal Melanoma · NCT05907954 | April 2027 Ongoing |
| Phase 1/2 IDE849 Small-cell Lung Cancer; Neuroendocrine Carcinomas · NCT07174583 | July 2029 Recruiting |
| Phase 3 Darovasertib Uveal Melanoma · NCT07015190 | October 2030 Recruiting |
| Phase 3 Darovasertib Uveal Melanoma · NCT07804186 | March 2034 Recruiting |
IDEAYA Biosciences Inc. reported $1.25B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $126M; at that rate the cash would last about 10 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |